

09/857325

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 19474X154/25	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/NZ 01/ 00130	International filing date (day/month/year) 29/06/2001	(Earliest) Priority Date (day/month/year) 30/06/2000
Applicant CASKEY, Phillip R.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.
☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1
☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NZ 01/00130

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 322 078 A (MILLS NICHOLAS JOHN) 19 August 1998 (1998-08-19) page 1, paragraph 4 -page 2, paragraph 3 page 10, paragraph 5 -page 11, paragraph 3; figures ---	1-4, 9, 10
X	DE 94 21 246 U (ALMED GMBH) 17 August 1995 (1995-08-17) the whole document ---	1-3, 5-9
A	US 5 562 643 A (JOHNSON JAMES B) 8 October 1996 (1996-10-08) abstract; figures --- -/--	1-3, 5-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

13 November 2001

Date of mailing of the international search report

20/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kousouretas, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NZ 01/00130

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ALLEN K L ET AL: "A SURVEY OF THE ANTIBACTERIAL ACTIVITY OF SOME NEW ZEALAND HONEYES" JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, GB, vol. 43, no. 12, December 1991 (1991-12), pages 817-822, XP000994760 ISSN: 0022-3573 the whole document -----</p>	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NZ 01/00130

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 2322078	A	19-08-1998	NONE	
DE 9421246	U	17-08-1995	DE 4423261 A1 DE 9421246 U1	04-01-1996 17-08-1995
US 5562643	A	08-10-1996	AU 2277595 A WO 9526779 A1	23-10-1995 12-10-1995

09/1857325

PCT


INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

12

Applicant's or agent's file reference P436300 DJJ	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International Application No. PCT/NZ01/00006	International Filing Date (day/month/year) 19 January 2001	Priority Date (day/month/year) 20 January 2000
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ A61K 35/39 A61P 3/10		
Applicant Diatranz Limited et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	<p>This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheet(s).</p>																								
3.	<p>This report contains indications relating to the following items:</p> <table border="0"> <tr> <td>I</td> <td><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td><input checked="" type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>	I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input checked="" type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input checked="" type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 5 July 2001	Date of completion of the report 13 December 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  K.G. ENGLAND Telephone No. (02) 6283 2292

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the drawings, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 9 to 55, 57 to 67, 69, 70, 72, 73, 94 to 104, 106-109	YES
	Claims 1 to 8, 56, 68, 71, 74 to 93, 105	NO
Inventive step (IS)	Claims 11 to 18, 28 to 35, 60 to 67, 72, 73, 98, 99, 102-104, 106 to 109	YES
	Claims 1 to 10, 19 to 27, 36 to 59, 68 to 71, 74 to 97, 100, 101, 105	NO
Industrial applicability (IA)	Claims 1 to 109	YES
	Claims nil	NO

2. Citations and explanations (Rule 70.7)

D1. WO 99/49734 A (Emory University and Bristol Myers-Squibb Company) 7 October 1999. See the whole document, in particular pages 49 and 50.

D2. NZ 250834 B (Diatranz) 26 May 1997. See the whole document.

D3. Riccardo Calafiore et al, "Transplantation of Pancreatic Islets Contained in Minimal Volume Microcapsules in Diabetic High Mammals." Annals of the New York Academy of Sciences. Vol. 875, 1999, pages 219-232. See in particular pages 222, 223, 224.

D4. Yi-lu Sun et al, "Normalisation of Diabetes in Spontaneously Diabetic Cynomolgus Monkeys by Xenografts of Microencapsulated Porcine Islets without Immunosuppression." Journal of Clinical Investigation, Vol. 98, No 6, 1996 pages 1417-1422. See in particular pages 1417, 1418 and 1421.

D5. Robert P. Lanza et al, "Biohybrid Artificial Pancreas: Long -Term Function of Discordant Islet Xenografts in Streptozotocin Diabetic Rats." Transplantation Vol. 56 No. 5 1993, pages 1067-1072. See in particular page 1067 and 1068.

D6. Yi-lu Sun et al, "Porcine Pancreatic Islets: Isolation, Microencapsulation and Xenotransplantation." Artificial Organs Vol. 17 No. 8 1993, pages 727-733. See in particular pages 727 and 728.

D7. Collin J. Weber et al "Evaluation of Graft-Host Response for Various Tissue Sources and Animal Models." Annals of the New York Academy of Sciences. Vol 875 1999, pages 233-254. See in particular pages 233, 239 and 240.

D8. AU 81864/98 A (Diatranz Limited) 11 March 1999. See the whole document.

D9. Takashi Maki et al "Porcine islet xenotransplantation utilizing a vascularised bioartificial pancreas." Annals of Transplantation, Vol. 2 No. 3, 1997, pages 69 to 71.

D1 discloses xenotransplantation of alginate/poly-L-ornithine encapsulated neonatal porcine islet cells for treatment of diabetes. The capsules are permeable to glucose and insulin but impervious to immunoglobulins

D2 and D8 disclose xenotransplantation of near full term porcine islet cells, isolated with collagenase, for treatment of diabetes, with treatment of the islets and the recipient using nicotinamide, and the maintenance of a casein free diet. The islets are maintained in a pathogen free culture but not encapsulated.

D3 discloses xenotransplantation of islet cells encapsulated in sodium alginate gelled with calcium and poly-L-ornithine, and not permeable to immunoglobulins. Nicotinamide is not mentioned.

D4 discloses xenotransplantation of mature porcine islet cells, isolated using collagenase and encapsulated in sodium alginate combined with poly-L-ornithine and a calcium salt. Nicotinamide, casein, protection of islet cells against damage and poly-L-ornithine are not discussed.

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 54 is not clear in its dependency on claims 1 to 18 since these do not define the preparation of a capsule.

Claim 56 is not fully supported by the description. The invention as described is limited to xenotransplantable capsules of cells treated with nicotinamide, but claim 56 is not so limited.

Claim 68, which refers to "step a)" has been appended to claim 47 for no apparent reason, and itself. Perhaps the range of claims intended was from 57 to 67

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of Box V

D5 discloses xenotransplantation of porcine and other islet cells isolated with collagenase and encapsulated in calcium gelled alginate, the whole enclosed in a insulin and glucose acrylic permeable membrane. Nicotinamide, casein, protection of islet cells against damage and poly-L-ornithine are not discussed.

D6 discloses xenotransplantation of porcine islet cells isolated with collagenase and encapsulated in a calcium gelled sodium alginate and poly-L-ornithine system. Nicotinamide, casein and protection of islet cells against damage are not discussed.

D7 discloses xenotransplantation of neonatal porcine islet cells encapsulated in a calcium gelled sodium alginate and poly-L-ornithine system. There is no discussion of nicotinamide, casein or protection of the cells against damage.

D9 discloses xenotransplantation of collagen-isolated porcine islet cells enclosed in an artificial pancreas composed of synthetic polymers permeable to insulin and glucose.

None of the cited documents disclose treatment of islets with IgF-1, gly-pro-glu tripeptide, antibiotics, the use of human serum albumen, anaesthetic agents, or anti-cholesterol drugs so claims 9, 11 to 18, 25, 28 to 35, 60 to 67, 72, 73, 98,99, and 101 to 103 defining one or more of these integers are novel and inventive.

Claim 56 and appended claims 68, 71, 76 to 93 and 105, which omit the use of nicotinamide are not novel and have no inventive step in comparison to all of the documents.

Claims 1 to 8, which omit the encapsulation of the cells are not novel and have no inventive step in comparison to documents D2 and D8.

The skilled operator would find it obvious to combine the disclosures of D2 or D8 and any one of D3, D4, D6 or D7 to produce a method of xenotransplantation using similarly or identically encapsulated islet cells prepared with collagenase, treated with nicotinamide and used in a patient on a casein free diet. In addition, it is obvious for the operator to choose porcine or human collagenase. Therefore claims 1 to 10, 19 to 27, 36 to 59, 68 to 71, 74 to 97, 100 and 101, defining only these integers have no inventive step in comparison to these documents.

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of Box I

Rule 67 lists the subject matter which under Article 34(4)(a)(i) an international preliminary examination is not required to be carried out. At item (iv) it specifies methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods, as such matter. However the agreement between WIPO and Australia further qualifies this by excepting from exclusion any subject matter which is examined under national grant procedures. Claims 57 to 104, 106, 107 and 109 have nonetheless been considered because the identified subject matter does not contravene Australian law.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/52871 A1

(51) International Patent Classification⁷: **A61K 35/39,**
A61P 3/10

507961 2 November 2000 (02.11.2000) NZ

(21) International Application Number: **PCT/NZ01/00006**

(22) International Filing Date: 19 January 2001 (19.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

502474	20 January 2000 (20.01.2000)	NZ
502475	20 January 2000 (20.01.2000)	NZ
502476	20 January 2000 (20.01.2000)	NZ
502473	20 January 2000 (20.01.2000)	NZ
502826	11 February 2000 (11.02.2000)	NZ
504520	12 May 2000 (12.05.2000)	NZ
504522	12 May 2000 (12.05.2000)	NZ
504521	12 May 2000 (12.05.2000)	NZ
504523	12 May 2000 (12.05.2000)	NZ
506287	10 August 2000 (10.08.2000)	NZ
506337	15 August 2000 (15.08.2000)	NZ

(71) Applicant (for all designated States except US): **DIA-TRANZ LIMITED** [NZ/NZ]; 19 Laureston Avenue, Papatoetoe, Auckland (NZ).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **ELLIOTT, Robert, Bartlet** [AU/NZ]; 19 Laureston Avenue, Papatoetoe, Auckland (NZ). **CALAFIORE, Riccardo** [IT/IT]; Dimisem, University of Perugia, Via E Dal Pozzo, I-06126 Perugia (IT). **BASTA, Guiseppe** [IT/IT]; Dimisem, University of Perugia, Via E Dal Pozzo, I-06126 Perugia (IT).

(74) Agents: **PARK, A., J. et al.**; Huddart Parker Building 1 Post Office Square, Wellington (NZ).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: **PREPARATION AND XENOTRANSPLANTATION OF PORCINE ISLETS**



(57) Abstract: The invention relates to developments in the treatment of diabetes in mammals. Particularly it relates to a method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of: (i) harvesting the pancreas of piglets at or near full term gestation, and (ii) extracting pancreatic β islet cells from the harvested pancreas wherein the islets (at least at some stage in the performance of the method) are exposed to nicotinamide. Further, the invention relates to a method of encapsulation of a xenotransplantable porcine islet preparation, and transplantation of such a preparation, or a capsule containing such a preparation, into an appropriate recipient mammal.

WO 01/52871 A1



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PREPARATION AND XENOTRANSPLANTATION OF PORCINE ISLETS

INTRODUCTION

The present invention relates to improvements in and/or relating to the treatment of diabetes using xenotransplantation. More particularly but not exclusively the present invention relates to the preparation of viable xenotransplantable porcine islets and/or the treatment of a mammalian patient (including humans) suffering from diabetes involving the transplantation into the mammal of viable porcine islets capable of producing insulin within the host.

BACKGROUND

Type 1 (insulin-dependent) diabetes mellitus is a common endocrine disorder that results in substantial morbidity and mortality, and leads to considerable financial costs to individual patients and healthcare systems.

Treatment with insulin, while life-saving, often does not provide sufficient control of blood glucose to prevent the feared complications of the disease, which has provided the impetus for intensive research into better methods of sustaining normoglycaemia.

Among the newer treatment strategies that have been proposed, transplantation of pancreatic β islet cells, obtained either from other humans or animals, has received the most attention worldwide. This is because transplantation can restore not only the insulin-secreting unit, but also the precise fine tuning of insulin release in response to multiple neural and humoral signals arising within and beyond the islets of Langerhans.

Human islet cell transplantation is limited by the shortage of human islet tissue. The use of pig islet cells is currently viewed as the most promising alternative since:

- (a) the supply of pig cells can be readily expanded by optimising the supply of donor animals;
- (b) pig and human insulin have close structural similarities; and
- (c) physiological glucose levels in pigs are similar to those in humans.

The rationale for this treatment approach (termed 'xenotransplantation') is that the implanted pig islets have the potential to mimic the normal physiological insulin response in type 1 diabetics such that near-normal blood glucose levels may be achievable without insulin administration or with a reduced requirement for it. As a consequence, long-term
5 diabetes complications may be prevented and patients should experience less hypoglycaemia than they do with the currently recommended 'intensive' insulin regimens.

OBJECT

It is an object of the present invention to provide a method of preparing porcine islets which
10 produces islets viable for xenotransplantation into a mammalian patient the islets being capable of producing insulin within a mammalian host, as well as the islet preparation so produced, or irrespectively or how produced, or a similiar form.

Alternatively or additionally, it is a further object to provide a method of treating a
15 mammalian patient suffering from diabetes which involves the xenotransplantation of porcine islets into the mammalian patient.

Alternatively or additionally, it is a further object to at least provide the public or medical community with a useful alternative approach to diabetes treatment.
20

STATEMENTS OF INVENTION

In a first aspect the invention consists in a **method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal**, the method including or comprising the
25 steps of:

- (I) harvesting the pancreas of piglets at or near full term gestation, and
- (ii) extracting pancreatic β islet cells from the harvested pancreas

wherein the islets (at least at some stage in the performance of the method) are exposed to nicotinamide.

30

Preferably the method includes or comprises the steps of:

- (I) harvesting the pancreas of piglets at or near full term gestation, and
- (ii) preparing a culture of the pancreatic β islet cells

- (iii) simultaneously with step (ii) and/or after step (ii) extracting pancreatic β islet cells from the culture of the harvested pancreas

5 Preferably said piglets from which the pancreatic β islet cells are extracted are at from -20 to +10 days full term gestation.

Preferably said piglets are at from -7 to +10 days full term gestation.

Preferably the extraction is performed using a suitable collagenase

Preferably the collagenase is selected from human Liberase® or porcine Liberase®.

Preferably said collagenase is human Liberase®.

- 10 Preferably the culture includes harvested pancreas in a supportive mammalian albumin substantially free of non-human microbiological agents.

Preferably the mammalian albumin is human serum albumin (HSA).

Preferably the islets are treated with nicotinamide after their extraction from the pancreas.

- 15 Preferably the method includes the further step of treating the islets with IgF-1 or the N-terminal tripeptide of IgF-1 (GPE).

Preferably the exposure to IgF₁ or to GPE is greater for those cells from piglets furthest from full term gestation, more preferably there is exposure to IgF₁ for all cells extracted irrespective of their relationship to full term gestation.

- 20 Preferably the pancreas and/or islets are subject to a trauma protecting agent selected from suitable anaesthetic agents.

Preferably the trauma protecting agent is lignocaine.

Preferably step (iii) of the method includes mechanically reducing the harvested pancreas in the presence of the islet trauma protecting agent.

Preferably an antibiotic is associated with the islet cells.

- 25 Preferably said antibiotic is ciproxin.

In another aspect the invention consists in a method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, said method including or comprising the steps of:

30

- (I) harvesting the pancreas of piglets at or near full term gestation, and
- (ii) preparing a culture of the pancreatic β islet cells
- (iii) simultaneously with step (ii) and/or after step (ii) extracting pancreatic β

islet cells from the culture of the harvested pancreas
and

- (iv) encapsulating the islet cells with a biocompatible xenotransplantable material, said material *in vivo* being both glucose and insulin porous,
5 wherein nicotinamide is introduced to the islets or islet cells prior to encapsulation at any one or more stages of the procedure.

Preferably said piglets at or near full term gestation from which the pancreatic β islet cells are extracted are at from -20 to +10 days full term gestation.

- 10 Preferably said piglets are at from -7 to +10 days full term gestation.

Preferably the extraction is performed using a suitable collagenase.

Preferably the collagenase is selected from human Liberase® or porcine Liberase®.

Preferably said collagenase is human Liberase®.

Preferably the culture includes harvested pancreas in a supportive mammalian albumin

- 15 substantially free of non-human microbiological agents.

Preferably the mammalian albumin is human serum albumin (HSA).

Preferably the islets are treated with nicotinamide after their extraction from the pancreas.

Preferably the method includes the further step of treating the islets with IgF-1 or the N-terminal tripeptide of IgF-1 (GPE).

- 20 Preferably the exposure to IgF₁ or to GPE is greater for those cells from piglets furthest from full term gestation but preferably there is exposure to IgF₁ for all cells extracted irrespective of their relationship to full term gestation.

Preferably the pancreas and/or islets are subject to a trauma protecting agent selected from suitable anaesthetic agents.

- 25 Preferably the trauma protecting agent is lignocaine.

Preferably step (iii) of the method includes mechanically reducing the harvested pancreas in the presence of the islet trauma protecting agent.

Preferably an antibiotic is associated with the islet cells.

Preferably said antibiotic is ciproxin.

- 30 Preferably said biocompatible material is a suitable alginate.

Preferably the alginate is in ultra pure form.

Preferably each islet or grouping of islets is entrapped in an *in vivo* insulin and glucose porous biocompatible alginate or alginate-like surround.

Preferably the encapsulation provides a surround which prevents, once implanted, direct tissue contact with the islets.

Preferably each encapsulation involves presenting islets and a suitable alginate solution into a source of compatible cations thereby to entrap the islets in a cation - alginate gel.

5 Preferably said cation alginate gel is calcium-alginate gel.

Preferably said alginate used in the solution is sodium alginate, and the islet and sodium alginate solution is presented as a droplet into a bath of suitable cations.

Preferably the islet and sodium alginate solution is of 1.6% w/w.

10 Preferably the islet and sodium alginate solution is presented as a droplet through a droplet generating needle.

Preferably the suitable cations are calcium chloride.

Preferably the gel encased islets are coated with a positively charged material and thereafter are provided with an outer coat of a suitable alginate.

Preferably the positive charging material is poly-L-ornithine.

15 Preferably the gel entrapping the islets within the outer coating is then liquified.

Preferably the liquification involves or comes about by the addition of sodium citrate.

Preferably the encapsulation produces capsules.

Preferably the capsules contain a plurality of islet cells.

Preferably the capsules contain substantially three islet cells.

20 Preferably the capsules have a diameter of substantially from about 300 to 400 microns.

Preferably following liquification of the alginate entrapping the islets there are the further steps of:

- washing the capsules

25 - further coating the capsules with alginate to neutralize any residual charge on the poly-L-ornithine coating and prevents direct contact of the poly-L-ornithine with tissues when the entire capsule is transplanted.

Preferably the alginate has been produced via a process involving the steps of:

Seaweed harvest→Washing→Alginate extraction→Filtration

→Precipitation→Drying.

30

In another aspect the invention is a **xenotransplantable capsule** prepared according to the above method.

In another aspect the present invention is a **xenotransplantable preparation** being or including viable porcine islets prepared according to a method of the present invention.

In still a further aspect the present invention consist in a **xenotransplantable capsule** of at least one porcine pancreatic β islet cell comprising at least one viable porcine pancreatic β islet cell enclosed in an *in vivo* glucose porous and insulin porous biocompatible material.

In another aspect the invention consists in a **method for treatment of a mammalian patient** suffering from diabetes which comprises:

- 10 (a) extracting pancreatic β islet cells from piglets at or near full term gestation;
- (b) Simultaneously with, and/or after a), treating said islets with nicotinamide,
- (c) encapsulating said islets in a biocompatible material which will allow *in vivo* glucose movement to and insulin movement from the islets, and
- 15 (d) injecting or otherwise implanting the encapsulated islet cells of step (c) so as to transplant into said mammalian patient an effective amount of viable piglet islet cells capable of producing insulin in the patient,

Preferably the method further includes the step of administering nicotinamide to the mammalian patient at least subsequent to transplantation.

- 20 Preferably the method further includes the step of prescribing to the patient, prior to or after the implantation step, a casein-free diet (as herein described).

Preferably the method further includes the step of exposure of the pancreatic β islet cells at some stage after extraction from the piglets and prior to encapsulation to IgF₁ or to GPE.

- 25 Preferably the harvesting of the islets at least during any substantial confrontation (eg; mincing and/or enzymatic challenge) is in the present of a trauma protecting agent.

Preferably the trauma protecting agent is used during the isolation and/or preparation thereof for encapsulation.

Preferably the agent is a trauma protecting agent is selected from suitable anaesthetic agents.

- 30 Preferably the trauma protecting agent is lignocaine.

Preferably the patient prior to, during or after the step (d) has been subjected to a cholesterol lowering drug regime.

Preferably the drug is of the "statin" family.

Preferably the drug is pravastatin.

Preferably the yield of viable porcine islets obtained from the extraction of step a) is enhanced by the use of a suitable collagenase.

Preferably the collagenase is selected from human Liberase® or porcine Liberase®.

- 5 Preferably said collagenase is human Liberase®.

Preferably the extraction of step a) includes mechanical treatment of the islets.

Preferably the mechanical treatment follows application of a suitable anaesthetic to the pancreatic tissue.

Preferably the anaesthetic is lignocaine.

- 10 Preferably said piglets from which the pancreatic β islet cells are extracted are at from -20 to +10 days full term gestation.

Preferably said piglets are at from -7 to +10 days full term gestation.

Preferably said biocompatible material is a suitable alginate.

Preferably the alginate is in ultra pure form.

- 15 Preferably each islet or grouping of islets is entrapped in an *in vivo* insulin and glucose porous biocompatible alginate or alginate-like surround.

Preferably the encapsulation provides a surround which prevents, once implanted, direct tissue contact with the islets.

Preferably each encapsulation involves presenting islets and a suitable alginate solution into

- 20 a source of compatible cations thereby to entrap the islets in a cation - alginate gel.

Preferably said cation alginate gel is calcium-alginate gel.

Preferably said alginate used in the solution is sodium alginate, and the islet and sodium alginate solution is presented as a droplet into a bath of suitable cations.

Preferably the islet and sodium alginate solution is of 1.6% w/w.

- 25 Preferably the islet and sodium alginate solution is presented as a droplet through a droplet generating needle.

Preferably the suitable cations are calcium chloride.

Preferably the gel encased islets are coated with a positively charged material and thereafter are provided with an outer coat of a suitable alginate.

- 30 Preferably the positive charging material is poly-L-ornithine.

Preferably the gel entrapping the islets within the outer coating is then liquified.

Preferably the liquification involves or comes about by the addition of sodium citrate.

Preferably the encapsulation produces capsules.

Preferably the capsules contain a plurality of islet cells.

Preferably the capsules contain substantially three islet cells.

Preferably the capsules have a diameter of substantially from about 300 to 400 microns.

Preferably following liquification of the alginate entrapping the islets there are the further

5 steps of:

- washing the capsules

- further coating the capsules with alginate to neutralize any residual charge on the poly-L-ornithine coating and prevents direct contact of the poly-L-ornithine with tissues when the entire capsule is transplanted.

10 Preferably the alginate has been produced via a process involving the steps of:

Seaweed harvest→Washing→Alginate extraction→Filtration
→Precipitation→Drying.

In yet another aspect the invention is a method for the treatment of a mammalian patient

15 suffering from or predisposed to diabetes, said method including or comprising the steps of:

- (A) (i) harvesting the pancreas of piglets at or near full term gestation,

- (ii) culturing the harvested pancreas in Mammalian Albumin substantially free of non-human microbiological agents,

- (iii) simultaneously with step (ii) and/or after step (ii), extracting the

20

islets from the harvested pancreas using a suitable Liberase®,

wherein the islets (at least at some stage in the performance of (A)) are exposed to nicotinamide;

- (B) (i) encapsulating the islets prepared by (A) with a suitable encapsulation material that allows both glucose and insulin movement

25

therethrough, and

- (ii) implanting the encapsulated porcine islets into the recipient mammal.

Preferably the Liberase® is selected from human Liberase® or porcine Liberase®.

Preferably the Liberase is human Liberase®.

30 Preferably the extraction of step a) includes mechanical treatment of the islets.

Preferably the mechanical treatment follows application of a suitable anaesthetic to the pancreatic tissue.

Preferably the anaesthetic is lignocaine.

Preferably the method further includes the step of administering nicotinamide to the recipient mammal prior to or after the implantation step.

Preferably the method further includes the step of prescribing for the patient, prior to or after the implantation step, a casein-free diet (as described herein).

- 5 Preferably the method further includes the step of subjecting the patient prior to or after the implantation step to a cholesterol lower drug regime.

Preferably the cholesterol lowering drug is of the "statin" family

Preferably said cholesterol lowering drug is pravastatin or simvastatin.

- 10 In a further aspect the present invention consists in **encapsulated pancreatic islets** of a kind useful in a method aforesaid.

In still a further aspect the present invention consists in **a method of porcine β islet cell production and/or method of xenotransplantation thereof in an encapsulated form**

- 15 when performed by a procedure substantially as hereinbefore described and/or substantially as hereinafter described and/or as shown in Figure 1 of the accompanying drawings.

In a further aspect the present invention consists in **any isolated porcine islets or xenotransplantable preparations including viable porcine islets** where the digestion has

- 20 been in accordance with the method in accordance with the present invention.

In yet another aspect the invention is **a method of treating a mammalian patient predisposed to or suffering from diabetes** which involves the xenotransplantation into such patient at least one capsule of the present invention.

25

DETAILED DISCUSSION

1. General

- The present invention recognises the ability to source appropriate islets from piglets which have similar structural similarities of insulin to humans, and similar physiological glucose levels to humans. The piglets used are at or near full term gestation. The islets are converted into an appropriate xenotransplantable source of islets with viability in a human being by following certain procedures in respect of the harvesting and extraction of the islets, the treatment of the islets prior to xenotransplantation as well as regimes of use of such islets.
- 30

The major advantage of porcine islet cell transplantation over human islet cell transplantation is that the islet cell source can be readily expanded, and the biosafety of the cells can be thoroughly explored prior to transplantation. From a practical viewpoint, pancreas removal and islet cell isolation can be performed expeditiously in an ideal environment.

Important considerations relevant to the use of porcine islet cells in transplantation approaches for type 1 diabetes include the following:

- The structural and biological similarities of porcine and human insulin
- The fact that porcine insulin has been used to treat diabetes for several decades (and has only been replaced by human sequence insulin relatively recently); and
- The similarity of physiological glucose levels in pigs and humans. (Weir & Bonner-Weir 1997). This effectively means that pig islet cells can be expected to react similarly to their human counterparts in maintaining equivalent blood glucose concentrations.

2. The Nature of the Disease causing Diabetes

Successful long-term allotransplantation of human islets can be achieved in over 80% of patients when the disease is caused by non-immune processes. In contrast, even islets obtained from a non-diabetic twin cannot reverse autoimmune diabetes long-term in the diabetic twin member. This emphasises the critical role of autoimmunity in the failure of islet transplantation. This observation has been validated in allotransplantation of rodents with diabetes caused by autoimmunity as compared with diabetes due to pancreatectomy or chemical β cell destruction. No large animal model of autoimmune diabetes exists. It is possible that the use of islets from different species (xenotransplantation) could avoid autoimmune destruction of transplanted islets, as the immune process of xenotransplant rejection is different to that of allotransplant rejection, but this is entirely hypothetical in humans.

3. Isolation and Preparation of Porcine Islet Cells for Xenotransplantation

3a. Animal Source and Transportation

All animals intended as a source of pancreatic tissue for xenotransplantation are obtained

from a specific pathogen-free (SPF) pig breeding facility which is maintained in accordance with the American Association for Accreditation of Laboratory Animal Care (AAALAC). The facility maintains a high-health status colony with excellent standards of husbandry, and operates a record system that is readily accessible and archived indefinitely.

- 5 Donor sows and sires are selected with the underlying objective of producing strong heterosis in donor litters.

3b. Isolation and Purification of Islet Cells

- Following surgical removal, the donor pancreases are transferred to a cleanroom facility for
10 further processing in a cold plastic container in 50ml tubes containing cold Hanks' Balanced Salt Solution (HBSS) with 0.2% human serum albumin (HSA) added. Blood samples from each donor are sent for virology testing and toxoplasma serology. Samples from each organ are kept in a freezer at -80°C for future testing if necessary.

15 3c. Digestion

- The islet cells are isolated by standard collagenase digestion of the minced pancreas via the procedure documented by Ricordi et al. (1990), though with some modifications. Using aseptic technique, the glands are distended with Liberase® (1.5mg/ml), trimmed of excess fat, blood vessels and connective tissue, minced, and digested at 37°C in a shaking water
20 bath for 15 minutes at 120 rpm. The digestion is achieved using lignocaine mixed with the Liberase® solution to avoid cell damage during digestion. Following the digestion process, the cells are passed through a sterile 400µm mesh into a sterile beaker. A second digestion process is used for any undigested tissue.
- 25 We have determined that much greater yields per neonatal pig pancreas can be obtained using either pig or human Liberase™ (eg; sourced in New Zealand from Roche) rather than collagenase. Whilst there is disclosure in "*Improved Pig Islet Yield and Post-Culture Recovery Using Liberase P1 Purified Enzyme Blend*", T J Cavanagh et al. Transplantation Proceedings 30, 367 (1998) and in "*Significant Progress In Porcine Islets Mass Isolation*
30 *Utilizing Liberase® HI For Enzymatic Low-Temperature Pancreas Digestion*", H. Brandhorst et al. Transplantation Vol 68, 355-361 No. 3, August 15, 1999 the yields therefore therein are low compared to those we have discovered. If, for example, in following the procedure of Brandhorst et al. there is a yield increase of islets over

collagenase of from 400 to say 800 with the procedure using human Liberase ® (ie; Liberase ® HI) as in the Brandhorst et al. procedure but confined to neonatal porcine islets such as those as 7 days post delivery extra ordinarily larger yields are possible, namely, the equivalent to from 400 which would be the case with crude collagenase to 30000 which as
5 can be seen as very much greater than that to be expected from following the procedure of Brandhorst et al. with pigs.

3d. Washing and Culture

The digested tissue is washed three times, and seeded into cell culture media RPMI 1640 to
10 which is added 2% human serum albumin (HSA), 10 mmol/L nicotinamide, and antibiotic (Ciproxin).

3e. Quality Control Procedures

To exclude any contamination of the tissue, quality control procedures are undertaken on
15 cell culture samples after isolation and before encapsulation. Three days after isolation, the cell culture is tested for microbiological contamination by accredited laboratories. Testing for porcine endogenous retrovirus (PERV) is undertaken at the Virology Laboratory, Auckland Hospital.

20 The *islet yield* is determined via dithizone (DTZ) staining of the cells. Dithizone is a zinc-chelating agent and a supravital stain that selectively stains zinc in the islets of Langerhans, producing a distinctive red appearance.

The *viability* of the islet cells is determined using acridin orange and propidium iodide.
25 Acridin orange is a fluorescent stain that readily passes through all cell membranes to stain the cytoplasm and nucleus. Bright green fluorescence in both the nucleus and cytoplasm on exposure to ultraviolet (UV) light denotes intact live cells. Conversely, propidium iodide is a fluorescent stain that cannot pass through an intact membrane. It emits a bright red fluorescence when exposed to UV light, and the presence of propidium iodide in a cell
30 nucleus indicates severe damage or a dead cell.

3f. Determination of *in vitro* Insulin Secretory Capacity

Static glucose stimulation (SGS) is used to assess *in vitro* function of the porcine islets by

exposing them to low and high concentrations of glucose and theophylline. Determination of the *in vitro* insulin secretory capacity is undertaken on both free islets (after 3 days in culture) and after their subsequent encapsulation.

5 **4. Xenotransplantation**

4a. The viability of the islets for xenotransplantation

The processes by which islets are purified prior to transplantation are traumatic to these highly specialised tissues. Such trauma can induce necrosis or apoptosis – the latter can be quite delayed.

10

Further trauma may result from encapsulation. Processes used by us in both the preparation of islets and their encapsulation have been optimised to ensure minimal damage to the islets. Such procedures have ensured zero warm ischaemia (compared with hours with most human islet preparations), have involved the use of nicotinamide to enhance successful *in vitro* explantation, have involved minimal incubation time with collagenase or Liberase, have involved swift non-traumatic encapsulation technology, have involved the use of IgF-1 (or the GPE tripeptide thereof), the use of an anaesthetic such as lignocaine, and the use of an antibiotic such as ciprofloxacin etc.

15

20 Our preferred preparation preferably uses neonatal (7-day old) islets which is crucial in both limiting islet trauma during purification, and assuring sufficient maturation of the islets for stimulated insulin production.

25

The IgF-1 (Human Insulin-like Growth Factor I) is used in order to induce unmaturing porcine islets to mature to their insulin-producing form. IgF-1 is a potent mitogenic growth factor that mediates the growth promoting activities of growth hormone postnatally. Both IgF-1 and IgF-2 are expressed in many cell types and may have endocrine, autocrine and paracrine functions. The preferred form of IgF-1 we have found to be the amino-terminal tripeptide glycine-proline-glutamate of IgF-1 (GPE).

30

4b. Alginate Encapsulation Procedure

Sodium alginate used for this procedure is extracted from raw material sources (seaweed) and prepared in a powdered ultrapure form. The sterile sodium alginate solution (1.6%) is

then utilised at the Diatranz Islet Transplant Centre to manufacture encapsulated islets.

Generally each encapsulation involves presenting islets and a suitable alginate solution (usually sodium alginate) into a source of compatible cations thereby to entrap the islets in
5 a cation - alginate gel (usually calcium-alginate gel).

The encapsulation procedure involves extruding a mixture of islets and sodium alginate solution (1.6%w/w) through a droplet generating needle into a bath of gelling cations (calcium chloride). The islets entrapped in the calcium-alginate gel are then coated with
10 positively charged poly-L-ornithine followed by an outer coat of alginate (0.05%). The central core of alginate is then liquefied by the addition of sodium citrate. Most capsules contain 3 islets and have a diameter of 300 to 400 μ m.

After liquification of the alginate entrapping the islets, the "capsules" are washed, and
15 again coated with alginate which neutralizes any residual charge on the poly-L-ornithine coating and prevents direct contact of the poly-L-ornithine with tissues when the entire capsule is transplanted.

The encapsulated islets are kept in cell culture, and then checked for contamination,
20 insulin release and viability before transplantation. They are only released for transplantation if all quality control tests are negative.

Ideally the alginate production process has involved the following steps:

Seaweed harvest→Washing→Alginate extraction→Filtration (preferably a 0.2 μ m
25 filter→Precipitation→Drying.

The ultrapure alginate used is ideally Kelco LV produced by Monsanto-Kelco, US and has the following specifications:

1. Viscosity: 2% - 100-300 cps (Brookfield 25°C, speed 3,60 rpm)
- 30 2. pH: 6.4-8.0
3. Protein content <0.5%
4. Filtration: through 0.2 μ m
5. Chemical analysis:

Ca: <100 ppm	Mg <40 ppm	Mn: <10 ppm
Cu: <40 ppm	Zn: <40 ppm	Sr: <40 ppm
Fe: <60 ppm	Pb: <50 ppm	As: <100ppb
Hg: <40 ppb	Si: <10 ppm	

- 5 6. Endotoxin level - measured by LAL test (at University of Perugia): 39 EU/g
 [NB. Any level below 100 EU/g in this test is considered endotoxin-free].
7. Molecular weight: 120,000 - 190,000 kD
8. Mannuronic acid (M) content: M fraction (F_m) 61% .
9. Guluronic acid (G) content: G fraction (F_G) 39%

10

Ideally the filtration has been with a multiple filtration process employing positively charged filters that remove any lipopolysaccharide content.

4c. Drugs used in the recipient

- 15 Transplantation does not require and avoids the need for cytotoxic agents to suppress the immune system. Such agents are able to enter the alginate microcapsule and cause islet toxicity, as well as causing systemic toxicity. Instead, nicotinamide and a special diet are used (for rationale, see section 1.4 below).
- 20 The transplantation procedures of our earlier patent specification have the ability over a period prior to rejection of providing porcine insulin. In this respect, we ourselves conducted clinical trials.

- 25 Four type 1 diabetic adolescents received 10,000 free islets/kg bodyweight by intraperitoneal injection. The islets were located from term piglets using the standard collagenase digestion, purification and culture techniques described in section 3.2. All four recipients received oral nicotinamide (1.5 g/day) and a casein-free as herein defined diet both pre- and post-transplantation. A prompt reduction in insulin requirements, which was not clearly dose-related, was noted in the first week after transplantation. The reduction in insulin dosage range from 21 to 32%, and the response lasted for up to 14 weeks.
- 30 However, insulin doses subsequently returned to their previous levels.

The most likely reason for the transplant failure in these patients was chronic rejection.

However, no adverse effects were noted.

We have now shown alginate-encapsulated porcine islet cell transplants in two human diabetic patients, prolonged functioning of the transplants. The islets were transplanted by intraperitoneal injection, one patient receiving 15,000 IEQ/kg (total 1,300,000 islets) and the other 10,000 IEQ/kg (total 930,000 islets). Both patients were treated pre- and post-transplantation with oral nicotinamide and a soy-based/casein-free as herein defined diet.

The preferred procedure as shown in Figure 1 was used for the preparation, the encapsulation being as aforesaid. Islet cells of -7 days to +10 days full gestation were used.

DESCRIPTION OF THE DRAWINGS

Preferred forms of the present invention or examples of working will now be described with reference to the accompanying drawings in which:

- 15
- Figure 1** shows a preferred procedure for harvesting, isolating and preparing islet cells (with either confinement or encapsulation) and the associated treatment regime for a diabetic human patient in order to receive ongoing benefit from the xenotransplantation,
- 20 **Figure 2** shows the effect of collagenase from various sources on islet yield and function,
- Figure 3** shows the stimulation index of Liberase® against Collagenase clearly showing that Liberase® preparations (both human and porcine at suitable concentrations) gave higher yields and function in vitro than an optimised concentration of Collagenase P,
- 25 **Figure 4** shows the stimulation index of free islets when comparing the use of ciproxin against a penicillin/streptomycin mix and against a control of no antibiotics,
- Figure 5** shows the results of exposure of neonatal porcine islets in culture with GPE in comparison with control cells.
- 30

5. Examples**5a. Examples of use of IgF-1**

*Note: in the following , different experiments used different islet preparations so control values vary.

5

- porcine islets in culture which were exposed to IgF-1, increased their insulin response to glucose, by up to a 3-fold increase.

10

15

	Incubated 24hrs with 0.1ug/ml IgF-1 after isolation	CONTROL- no IgF-1
Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	236uU/hr/100IEQ	75.2uU/hr/100IEQ

20

- A concentration of 0.1ug/ml IgF-1 in culture is sufficient to produce optimal insulin secretion during glucose challenge. No further benefit was achieved by increasing the concentration of IgF-1.

25

	Incubated 24hrs with 0.1ug/ml IgF-1	Incubated 24hrs with 1.0 ug/ml IgF-1
Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	58uU/hr/100IEQ	56.8uU/hr/100IEQ

30

- Variations on the duration of IgF-1 exposure were tried on the porcine islet cells. However no increased benefit was found on culturing the islets with IgF-1 beyond a 24hrs period, post isolation.

5

	Incubated 7 days With 0.1ug/ml IgF-1	Incubated 24hrs with 1.0 ug/ml IgF-1
Insulin secretion In response to 19.4mM Glucose +10mM Theophylline 7days post isolation	58uU/hr/100IEQ	57.5uU/hr/100IEQ

- This increased insulin production persisted to 14 days post IgF-1 exposure. Longer durations are yet to be investigated.

10

	14 days post IgF-1 Exposure	3 days post IgF-1 Exposure
Insulin secretion In response to 19.4mM Glucose + 10mM Theophylline	1.3-fold increase Compared to control	1.5-fold increase Compared to control

- 15
- Withdrawal of Nicotinamide from the culture media eliminated the benefit of IgF-1 on islet insulin production.

20

	Incubated 3 days With 0.1ug/ml IgF-1 Without Nicotinamide	Incubated 3 days With culture Media Without Nicotinamide
Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	47.6uU/hr/100IEQ	55.9uU/hr/100IEQ

- 25
- A concentration of 0.1ug/ml IgF-2 during culturing appeared to increase insulin production of porcine islet cells, after an initial exposure of 24 hrs. However, this increase was transient to 3 days post exposure.

30

	Incubated 24hrs With 0.1ug/ml IgF-2 day 1.	Control
Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	105.8/100IEQ	75.2r/100IEQ

	Incubated 24hrs With 0.1ug/ml IgF-2 day 1.	Control
5 Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	32uU/hr/100IEQ	39.8 uU/hr/100IEQ

- Prolonged exposure to IgF-2 beyond 24hrs, failed to increase the insulin production of the islet cells in response to glucose.

	Incubated 24hrs With 0.1ug/ml IgF-2 day 1.	Control
10 Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	105.8/100IEQ	75.2r/100IEQ

15

	Incubated 7 days With 0.1ug/ml IgF-2	Control
20 Insulin secretion In response to 19.4mM Glucose +10mM Theophylline After 7 days culture Post isolation	38.4uU/hr/100IEQ	39.8uU/hr/100IEQ

5b. Effect of N-Terminal Tripeptide (GPE) of Insulin like growth factor (IGF-1) on the function of neonatal porcine islet cells.

- GPE is a tripeptide (gly-pro-glu) derived from IGF-1. It is a novel neuroactive peptide with a potent effect on acetylcholine and dopamine release in cortical slices. Previous studies done using GPE support the concept that the proteolytic products of the IGF-1 precursor play a role in the regulation of brain functions.

The aim of this example was to present the effect of GPE on the function of isolated porcine islets in vitro.

Method

- Islet cell isolation with 2 pancreases;

- Isolation following the previously discussed protocol;
- RPMI media added with Ciproxin, nicotinamide, Human serum albumin
- GPE, IGF1 (1-3), Bachem AG, Lot No.0538925, stock solution of 100 ug/ml (in water): dilute further in RPMI medium to the final concentrations: 1ug/ml (1:100),
5 0.1 ug/ml (1: 1000) and 0.01 ug/ml (1: 10 000)

1. GPE 0.01ug/ml
2. GPE 0.1ug/ml
3. GPE 1.0ug/ml

10

Keep the cells 3 days in culture before Static Glucose Stimulation (SGS). SGS involves exposure of the cells to low and high concentration of glucose to check insulin production. Using 0.1 ug/ml concentration add GPE to two plates 24 hours before SGS (day 2 after isolation)

15

Results of Example Sb

Exposure of neonatal porcine islets in culture to GPE increased the insulin response to glucose up to 11.5 compared with the control cells. (Stimulation Index control 13.3 compared to 24.8 when GPE was used) Viability of the cells was >85% DTZ, AO/PI

20 staining)

A concentration of 0.01ug/ml of GPE in culture is sufficient to produce optimal response during glucose challenge. No further benefit was achieved by increasing the concentration of GPE in culture. See Figure 5 below.

25

The results suggest that GPE could be used during porcine islet cell culture to improve the quality and function of the cells before transplantation. Furthermore GPE is a novel neuroactive peptide found in human brain.

- 30 **5c. Examples of the effect of lignocaine when used during porcine pancreatic digestion, on islet yield and viability.**

Lignocaine is a membrane stabiliser and phospholipase A2 inhibitor. When used at a 1mM

concentration during Collagenase digestion of 7d old porcine pancreas, a 2-fold increase in islet yield is produced.

Islet endocrine function was assessed after 3 days in culture via static glucose stimulation.

- 5 Islets isolated with Lignocaine during digestion produced a 3-fold increase in insulin secretion in response to glucose challenge.

	Collagenase alone	Collagenase + 1mM Lignocaine
Average islet yield	40,960 IEQ/g	88,183 IEQ/g

10

	Collagenase alone	Collagenase + 1mM Lignocaine
Insulin secretion in response to 19.4mM Glucose +10mM Theophylline After 3 days culture Post isolation	46.4 uU/hr/100IEQ	163.8 uU/hr/100IEQ

15

Conclusion: The use of Lignocaine during pancreatic digestion increases the insulin production/g of pancreas by 6-fold.

20

5d. Examples of the effects of Ciproxin on Islet function as assessed by static glucose stimulation.

Freshly prepared neonatal pig islets were prepared by standard isolation procedure and cultured for two days in RPMI medium with standard additions.

- 25 Streptomycin (100mcg/ml) and Penicillin (100U/ml) were included in one flask and Ciproxin (3 mcg/ml) in another.

The islets were harvested and an aliquot subjected to stimulation with theophylline and high glucose.

The comparative insulin release from the islets---a measure of viability is shown in Figure

30 4.

5e. Examples of the effects of collagenase from various sources on islet yield and function

Pancreases of neonatal piglets aged 7 days were obtained as above and islets extracted by the same process, varying only the source and amount of collagenase. The yield/gram of pancreas is shown in the Figure.

Islets extracted using these variations in collagenase source and amount were assessed for viability using propidium iodide and dithizone for insulin content.

DTZ staining >85%

10 AO/PI >85%

The islets were then assessed for functionality by static glucose stimulation as above. The results are shown in the Figure below.

It is apparent that the Liberase® preparations at suitable concentrations gave higher yields and function in vitro than the previously optimised concentration of Collagenase P.

15

5f. Examples of the comparative effectiveness of islets prepared with Liberase P or H in vivo

Islets prepared with the best concentration of Liberase® P and H in this way were injected intraperitoneally into CD1 mice made diabetic by intravenous streptozotocin. The dose used was 10 islets/g body weight of mouse. Ten days after such treatment the number of mice no longer diabetic was assessed.

25

1/7 of the mice treated with the islets isolated with Liberase® P and 4/7 of those isolated with Liberase H were non diabetic.

Similar experiments were performed using spontaneously diabetic NOD mice. Of the surviving mice at 10 days after transplantation 3/7 of the Liberase P treated islets and 3/3 of the Liberase H islets were no longer diabetic

30 5g. Example of Islet Encapsulation Procedure

The novel medium size microcapsules (300-400µ MSM) are prepared by atomizing the islet-alginate suspension through a special microdroplet generator.

Sodium alginate used for this procedure is extracted from raw material sources (seaweed) and prepared in powdered ultrapure form (Keltone LVCR).

5 The encapsulation procedure involves extruding a mixture of islets and sodium alginate solution (1.6%) through a droplet generating needle into a bath of gelling cations (calcium chloride). The islets entrapped in the calcium-alginate gel are then coated with positively charged poly-L-ornithine followed by an outer coat of alginate (0.05%). The central core of alginate is then liquified by the addition of sodium citrate. Most capsules contain 3 islets and have a diameter of 300 to 400 μ m.

10

The encapsulated islets are kept in cell culture, and then checked for contamination, insulin release and viability before transplantation.

DEFINITIONS

15 As used herein:

- "Administering" includes self-administering;
- "Casein-free" when referring to milk as used herein refers to milk which does not contain a diabetogenic factor, particularly to milk containing no variant of β -casein which stimulates diabetogenic activity in humans. With reference to International
20 PCT Application WO 96/14577, a non-diabetogenic variant for example, may be the A2 variant of β -casein. The full contents of PCT/NZ95/00114 (WO 96/14577) and PCT/NZ96/00039 (WO 96/36239) are here included by way of reference.
- "Casein-free" as used herein in respect of dietary considerations means at least a
25 substantial avoidance (preferably total avoidance) of such milk containing or derived diabetogenic factors.
- *IgF1* is Human Insulin-like Growth Factor I and is a potent mitogenic growth factor that mediates the growth promoting activities of growth hormone postnatally. Both IGF-1 and IGF-2 are expressed in many cell types and may have endocrine, autocrine and paracrine functions.
- 30 - The *N-terminal tripeptide of Ig F-1* or "*GPE*" is the amino-terminal tripeptide glycine-proline-glutamate of IGF-1.
- "*mammalian albumin*" as used herein means serum albumin from mammals,

preferably human serum albumin (HSA).

- "*appropriate collagenase*" means preferably Liberase ®, ideally human or porcine, ideally Liberase H ®.

- "*mechanically reduced*" as used herein includes any process where pancreatic tissue is increased in surface area eg, mechanical or water jet shredding, grinding, mincing, etc...

CLAIMS:

1. A method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of:
 - 5 (I) harvesting the pancreas of piglets at or near full term gestation, and
 - (ii) extracting pancreatic β islet cells from the harvested pancreaswherein the islets (at least at some stage in the performance of the method) are exposed to nicotinamide.
2. A method as claimed in claim 1 wherein the method includes or comprises the steps of:
 - 10 (I) harvesting the pancreas of piglets at or near full term gestation, and
 - (ii) preparing a culture of the pancreatic β islet cells
 - (iii) simultaneously with step (ii) and/or after step (ii) extracting pancreatic β islet cells from the culture of the harvested pancreasand the islets (at least at some stage in the performance of the method) are exposed to nicotinamide.
3. A method as claimed in Claim 1 or 2 where the piglets from which the pancreatic β islet cells are extracted are at from -20 to +10 days full term gestation.
4. A method as claimed in claim 3 wherein the piglets are at from -7 to +10 days full term. gestation.
5. A method as claimed in any one of the preceding claims wherein the extraction is performed using a suitable collagenase.
6. A method as claimed in claim 5 wherein the collagenase is selected from human Liberase® or porcine Liberase®.
7. A method as claimed in claim 6 wherein the collagenase is human Liberase®.
8. A method as claimed in any one of the preceding claims wherein the culture includes harvested pancreas in a supportive mammalian albumin substantially free of non-human microbiological agents.
9. A method as claimed in claim 8 wherein the mammalian albumin is human serum albumin (HSA).
10. A method as claimed in any one of the preceding claims wherein the islets are treated with nicotinamide after their extraction from the pancreas.

11. A method as claimed in any one of the preceding claims wherein the method includes the further step of treating the islets with IgF-1 or the N-terminal tripeptide of IgF-1 (GPE).
12. A method as claimed in claim 11 wherein the exposure to IgF₁ or to GPE is greater for those cells from piglets furthest from full term gestation.
13. A method as claimed in claim 11 or 12 wherein there is exposure to IgF₁ for all cells extracted irrespective of their relationship to full term gestation.
14. A method as claimed in any one of the preceding claims wherein the pancreas and/or islets are subject to a trauma protecting agent selected from suitable anaesthetic agents.
15. A method as claimed in claim 14 wherein the trauma protecting agent is lignocaine.
16. A method as claimed in any one of the preceding claims wherein step (iii) of the method includes mechanically reducing the harvested pancreas in the presence of the islet trauma protecting agent.
17. A method as claimed in any one of the preceding claims wherein an antibiotic is associated with the islet cells.
18. A method as claimed in claim 17 wherein said antibiotic is ciproxin.
19. **A method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, said method including or comprising the steps of:**
 - (i) harvesting the pancreas of piglets at or near full term gestation, and
 - (ii) preparing a culture of the pancreatic β islet cells
 - (iii) simultaneously with step (ii) and/or after step (ii) extracting pancreatic β islet cells from the culture of the harvested pancreasand
 - (iv) encapsulating the islet cells with a biocompatible xenotransplantable material, said material *in vivo* being both glucose and insulin porous, wherein nicotinamide is introduced to the islets or islet cells prior to encapsulation at any one or more stages of the procedure.
20. A method as claimed in claim 19 wherein the piglets at or near full term gestation from which the pancreatic β islet cells are extracted are at from -20 to +10 days full term gestation.

21. A method as claimed in claim 20 wherein the piglets are at from -7 to +10 days full term gestation.
22. A method as claimed in any one of claims 19 to 21 wherein the extraction is performed using a suitable collagenase
- 5 23. A method as claimed in claim 22 wherein the collagenase is selected from human Liberase® or porcine Liberase®.
24. A method as claimed in claim 23 wherein the collagenase is human Liberase®.
25. A method as claimed in any one of claims 19 to 24 wherein the culture includes harvested pancreas in a supportive mammalian albumin substantially free of non-
10 human microbiological agents.
26. A method as claimed in claim 25 wherein the mammalian albumin is human serum albumin (HSA).
27. A method as claimed in any one of claims 19 to 26 wherein the islets are treated with nicotinamide after their extraction from the pancreas.
- 15 28. A method as claimed in any one of claims 19 to 27 wherein the method includes the further step of treating the islets with IgF-1 or the N-terminal tripeptide of IgF-1 (GPE).
29. A method as claimed in claim 28 wherein the exposure to IgF₁ or to GPE is greater for those cells from piglets furthest from full term gestation.
- 20 30. A method as claimed in claim 28 or 29 wherein there is exposure to IgF₁ for all cells extracted irrespective of their relationship to full term gestation.
31. A method as claimed in any one of claims 19 to 30 wherein the pancreas and/or islets are subject to a trauma protecting agent selected from suitable anaesthetic agents.
32. A method as claimed in claim 31 wherein the trauma protecting agent is lignocaine.
- 25 33. A method as claimed in any one of claims 19 to 32 wherein step (iii) of the method includes mechanically reducing the harvested pancreas in the presence of the islet trauma protecting agent.
34. A method as claimed in any one of claims 19 to 33 wherein an antibiotic is associated with the islet cells.
- 30 35. A method as claimed in claim 34 wherein the antibiotic is ciproxin.
36. A method as claimed in any one of claims 19 to 35 wherein the biocompatible material is a suitable alginate.

37. A method as claimed in claim 36 wherein the alginate is in ultra pure form.
38. A method as claimed in any one of claims 19 to 37 wherein each islet or grouping of islets is entrapped in an *in vivo* insulin and glucose porous biocompatible alginate or alginate-like surround.
- 5 39. A method as claimed in claim 38 wherein the encapsulation provides a surround which prevents, once implanted, direct tissue contact with the islets.
40. A method as claimed in claim 39 wherein each encapsulation involves presenting islets and a suitable alginate solution into a source of compatible cations thereby to entrap the islets in a cation - alginate gel.
- 10 41. A method as claimed in claim 40 wherein the cation alginate gel is calcium-alginate gel.
42. A method as claimed in claim 41 wherein the alginate used in the solution is sodium alginate, and the islet and sodium alginate solution is presented as a droplet into a bath of suitable cations.
- 15 43. A method as claimed in claim 42 wherein the islet and sodium alginate solution is of 1.6% w/w.
44. A method as claimed in claim 43 wherein the suitable cations are calcium chloride.
45. A method as claimed in claim 44 wherein the gel encased islets are coated with a positively charged material and thereafter are provided with an outer coat of a suitable
20 alginate.
46. A method as claimed in claim 45 wherein the positive charging material is poly-L-ornithine.
47. A method as claimed in claim 46 wherein the gel entrapping the islets within the outer coating is then liquified.
- 25 48. A method as claimed in claim 47 wherein the liquification involves or comes about by the addition of sodium citrate.
49. A method as claimed in any one of claims 19 to 48 wherein the encapsulation produces capsules.
50. A method as claimed in claim 49 wherein the capsules contain a plurality of islet
30 cells.
51. A method as claimed in claim 50 wherein the capsules contain substantially three islet cells.

52. A method as claimed in claim 50 wherein the capsules have a diameter of substantially from about 300 to 400 microns.
53. A method as claimed in claim 52 wherein following liquification of the alginate entrapping the islets there are the further steps of:
- 5 - washing the capsules
- further coating the capsules with alginate
54. A **xenotransplantable capsule** prepared according to the method as claimed in anyone of claims 1 to 53.
55. A **xenotransplantable preparation** being or including viable porcine islets prepared according to a method as claimed in anyone of claims 1 to 53.
- 10 56. A **xenotransplantable capsule** of at least one porcine pancreatic β islet cell comprising at least one viable porcine pancreatic β islet cell enclosed in an *in vivo* glucose porous and insulin porous biocompatible material.
57. A **method for treatment of a mammalian patient** suffering from diabetes which comprises:
- 15 (a) extracting pancreatic β islet cells from piglets at or near full term gestation;
- (b) Simultaneously with, and/or after (a), treating said islets with nicotinamide,
- (c) encapsulating said islets in a biocompatible material which will allow *in vivo* glucose movement to and insulin movement from the islets, and
- 20 (d) injecting or otherwise implanting the encapsulated islet cells of step (c) so as to transplant into said mammalian patient an effective amount of viable piglet islet cells capable of producing insulin in the patient,
58. A method as claimed in claim 57 wherein the method further includes the step of administering nicotinamide to the mammalian patient at least subsequent to
- 25 transplantation.
59. A method as claimed in claim 57 or 58 wherein the method further includes the step of prescribing to the patient, prior to or after the implantation step, a casein-free diet (as herein described).
60. A method as claimed in any one of claims 47 to 59 wherein the method further includes the step of exposure of the pancreatic β islet cells at some stage after
- 30 extraction from the piglets and prior to encapsulation to IgF₁ or to GPE.
61. A method as claimed in any one of claims 47 to 60 wherein the harvesting of the

- islets at least during any substantial confrontation (eg: mincing and/or enzymatic challenge) is in the present of a trauma protecting agent.
62. A method as claimed in claim 61 wherein the trauma protecting agent is used during the isolation and/or preparation thereof for encapsulation.
- 5 63. A method as claimed in claim 62 wherein the agent is a trauma protecting agent is selected from suitable anaesthetic agents.
64. A method as claimed in claim 63 wherein the trauma protecting agent is lignocaine.
65. A method as claimed in any one of claims 47 to 62 wherein the patient prior to, during or after the step (d) has been subjected to a cholesterol lowering drug regime.
- 10 66. A method as claimed in claim 65 wherein the drug is of the "statin" family.
67. A method as claimed in claim 66 wherein the drug is pravastatin.
68. A method as claimed in any one of claims 47 to 68 wherein the yield of viable porcine islets obtained from the extraction of step a) is enhanced by the use of a suitable collagenase.
- 15 69. A method as claimed in claim 68 wherein the collagenase is selected from human Liberase® or porcine Liberase®.
70. A method as claimed in claim 69 wherein the collagenase is human Liberase®.
71. A method as claimed in any one of claims 47 to 70 wherein the extraction of step a) includes mechanical treatment of the islets.
- 20 72. A method as claimed in claim 71 wherein the mechanical treatment follows application of a suitable anaesthetic to the pancreatic tissue.
73. A method as claimed in claim 72 wherein the anaesthetic is lignocaine.
74. A method as claimed in any one of claims 47 to 73 wherein the piglets from which the pancreatic β islet cells are extracted are at from -20 to +10 days full term
- 25 gestation.
75. A method as claimed in claim 74 wherein the piglets are at from -7 to +10 days full term gestation.
76. A method as claimed in any one of claims 47 to 75 wherein the biocompatible material is a suitable alginate.
- 30 77. A method as claimed in claim 76 wherein the alginate is in ultra pure form.
78. A method as claimed in any one of claims 47 to 77 wherein each islet or grouping of islets is entrapped in an *in vivo* insulin and glucose porous biocompatible alginate or

alginate-like surround.

79. A method as claimed in claim 78 wherein the encapsulation provides a surround which prevents, once implanted, direct tissue contact with the islets.
80. A method as claimed in claim 79 wherein each encapsulation involves presenting
5 islets and a suitable alginate solution into a source of compatible cations thereby to entrap the islets in a cation - alginate gel.
81. A method as claimed in claim 80 wherein the cation alginate gel is calcium-alginate gel.
82. A method as claimed in claim 81 wherein the alginate used in the solution is sodium
10 alginate, and the islet and sodium alginate solution is presented as a droplet into a bath of suitable cations.
83. A method as claimed in claim 82 wherein the islet and sodium alginate solution is of 1.6% w/w.
84. A method as claimed in claim 83 wherein the suitable cations are calcium chloride.
- 15 85. A method as claimed in claim 84 wherein the gel encased islets are coated with a positively charged material and thereafter are provided with an outer coat of a suitable alginate.
86. A method as claimed in claim 85 wherein the positive charging material is poly-L-ornithine.
- 20 87. A method as claimed in claim 86 wherein the gel entrapping the islets within the outer coating is then liquified.
88. A method as claimed in claim 87 wherein the liquification involves or comes about by the addition of sodium citrate.
89. A method as claimed in any one of claims 47 to 88 wherein the encapsulation
25 produces capsules.
90. A method as claimed in claim 89 wherein the capsules contain a plurality of islet cells.
91. A method as claimed in claim 90 wherein the capsules contain substantially three islet cells.
- 30 92. A method as claimed in claim 91 wherein the capsules have a diameter of substantially from about 300 to 400 microns.
93. A method as claimed in claim 92 wherein following liquification of the alginate

entrapping the islets there are the further steps of:

- washing the capsules
- further coating the capsules with alginate

- 5 94. A method for the treatment of a mammalian patient suffering from or predisposed to diabetes, said method including or comprising the steps of:
- 10 (A) (i) harvesting the pancreas of piglets at or near full term gestation,
(ii) culturing the harvested pancreas in Mammalian Albumin substantially free of non-human microbiological agents,
(iii) simultaneously with step (ii) and/or after step (ii), extracting the islets from the harvested pancreas using a suitable Liberase®,
wherein the islets (at least at some stage in the performance of (A)) are exposed to nicotinamide;
- 15 (B) (i) encapsulating the islets prepared by (A) with a suitable encapsulation material that allows both glucose and insulin movement therethrough, and
(ii) implanting the encapsulated porcine islets into the recipient mammal.
95. A method as claimed in claim 94 wherein the Liberase® is selected from human Liberase® or porcine Liberase®.
96. A method as claimed in claim 95 wherein the Liberase® is human Liberase®.
- 20 97. A method as claimed in any one of claim 94 to 96 wherein the extraction of step a) includes mechanical treatment of the islets.
98. A method as claimed in claim 97 wherein the mechanical treatment follows application of a suitable anaesthetic to the pancreatic tissue.
99. A method as claimed in claim 98 wherein the anaesthetic is lignocaine.
- 25 100. A method as claimed in any one of claims 94 to 99 wherein the method further includes the step of administering nicotinamide to the recipient mammal prior to or after the implantation step.
101. A method as claimed in any one of claims 94 to 100 wherein the method further includes the step of prescribing for the patient, prior to or after the implantation step, a casein-free diet (as described herein).
- 30 102. A method as claimed in any one of claims 94 to 101 wherein the method further includes the step of subjecting the patient prior to or after the implantation step to a

cholesterol lower drug regime.

103. A method as claimed in claim 102 wherein the cholesterol lowering drug is of the "statin" family
104. A method as claimed in claim 103 wherein the cholesterol lowering drug is pravastatin or simvastatin.
105. **Encapsulated pancreatic islets** of a kind useful in the method of any one of claims 57 to 104.
106. **A method of treating a mammalian patient predisposed to or suffering from diabetes** which involves the xenotransplantation into such patient a capsule as claimed in claim 56.
107. **A method of treating a mammalian patient predisposed to or suffering from diabetes** which involves the xenotransplantation into such patient a xenotransplantable preparation as claimed in claim 55.
108. **A method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal** substantially as herein described with reference to one or more of the Figures and/or Examples.
109. **A method for treatment of a mammalian patient suffering from diabetes** substantially as herein described with reference to one or more of the Figures and/or Examples.




FIGURE 1




**FIGURE 2****FIGURE 3**

FIGURE 4






FIGURE 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ01/00006

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. ⁷: A61K 35/39 A61P 3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Chemical Abstracts, WPAT, MEDLINE: islet*, porcine/pig, *transplant

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 99/49734 A (Emory University and Bristol Myers-Squibb Company) 7 October 1999. See the whole document, in particular pages 49 and 50.	56, 68, 71, 76 to 85, 87 to 93, 105 and 106 1 to 109
X Y	NZ 250834 B (Diatranz) 26 May 1997. See the whole document	1 to 5, 8 and 10 9, 19 to 27, 33, 36 to 50, 52 to 56, 57 to 59, 71, 76 to 90, 92 to 97, 100, 101, 105 to 107

☒ Further documents are listed in the continuation of Box C ☒ See patent family annex

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	--	---

Date of the actual completion of the international search

12 April 2001

Date of mailing of the international search report

26 April 2001

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaaustralia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

K.G. ENGLAND
Telephone No : (02) 6283 2292

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ01/00006

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	Riccardo Calafiore et al, "Transplantation of Pancreatic Islets Contained in Minimal Volume Microcapsules in Diabetic High Mammals". Annals of the New York Academy of Sciences. Vol. 875, 1999, pages 219-232. See in particular pages 222, 223, 224.	56, 68, 71, 76 to 82, 89, 105 and 106 1-109
X A	Yi-lu Sun et al, "Normalisation of Diabetes in Spontaneously Diabetic Cynomologus Monkeys by Xenografts of Microencapsulated Porcine Islets without Immunosuppression". Journal of Clinical Investigation, Vol. 98, No 6, 1996 pages 1417-1422. See in particular pages 1417, 1418 and 1421.	56, 68, 71, 76 to 90, 92, 105 and 106. 1 to 109
X A	Robert P. Lanza et al, "Biohybrid Artificial Pancreas: Long -Term Function of Discordant Islet Xenografts in Streptozotocin Diabetic Rats". Transplantation Vol. 56 No. 5 1993 pages 1067-1072. See in particular page 1067 and 1068.	56, 68, 71, 76 to 83, 84, 89, 90 and 106 1 to 109
X A	Yi-lu Sun et al, "Porcine Pancreatic Islets: Isolation, Microencapsulation and Xenotransplantation". Artificial Organs Vol. 17 No. 8 1993 pages 727-733. See in particular pages 727 and 728.	56, 68, 71, 76 to 90, 93, 105 and 106 1 to 109
X Y A	Collin-J. Weber et al "Evaluation of Graft-Host Response for Various Tissue Sources and Animal Models". Annals of the New York Academy of Sciences. Vol 875 1999 pages 233-254. See in particular pages 233, 239 and 240	56, 68, 71, 75 to 85 83 to 92 1 to 109
X Y	AU 81864/98 A (Diatranz Limited) 11 March 1999. See the whole document	1 to 5, 8 and 10 9, 19 to 27, 33, 36 to 50, 52 to 56, 57 to 59, 71, 76 to 90, 92 to 97, 100, 101, 105 to 107
A	Takashi Maki et al "Porcine islet xenotransplantation utilizing a vascularised bioartificial pancreas". Annals of Transplantation, Vol. 2 No. 3, 1997 pages 69 to 71	1 to 109

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/NZ01/00006

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member	
NZ	250834	US	6090400	US	6146653
WO	49734/99	AU	32067/99	EP	984699
END OF ANNEX					